Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity.
about
Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexedDual inhibition of EGFR at protein and activity level via combinatorial blocking of PI4KIIα as anti-tumor strategy.Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.Role of cell cycle in epidermal growth factor receptor inhibitor-mediated radiosensitization.Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt.Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.Recent advances in combined modality therapyEarly tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer.Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.(-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cellsInhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells.Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a reviewEfficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts.KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated β-TrCP1 degradation.Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update.Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor.High expression of SGTA in esophageal squamous cell carcinoma correlates with proliferation and poor prognosis.Cisplatin and ultra-violet-C synergistically down-regulate receptor tyrosine kinases in human colorectal cancer cellsPreclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.Regulation of EGFR protein stability by the HECT-type ubiquitin ligase SMURF2.Loss of EGFR induced autophagy sensitizes hormone refractory prostate cancer cells to adriamycin.Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancerCaffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway.Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinomaUltraviolet irradiation can induce evasion of colon cancer cells from stimulation of epidermal growth factor.Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics.ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.Depicting changes in tumor biology in response to cetuximab mono- or combination therapy by apoptosis and proliferation imaging using 18F-ICMT-11 and 3'-Deoxy-3'-[18F]Fluorothymidine (18F-FLT) PET.
P2860
Q33274781-F47D10A4-17BE-42EA-80B1-AC23AE4C604DQ33632845-A81372AB-71C6-4777-B64A-63175C19E0FAQ33854787-27191309-63C4-40AB-8A81-18C149144AECQ34861855-BEE01F40-F801-475F-800D-F5EF30D3C401Q34985788-D9C1A9C1-9E99-4E18-8E27-B257A0FB1AC2Q35167467-5A84D298-CA09-45B1-8FB9-1F6A6733EFD7Q35191014-9A533DE4-D081-45ED-8CC2-4BE6140B1E8AQ35228445-9CA40CCD-2763-4534-8E8C-9AE6D31152CCQ35584002-84D63115-DF61-414C-909C-31395F1D4C2DQ36012652-F6D3DFE5-658B-41A4-9C23-72BCEF4E40F5Q36088163-D8EB1120-07F1-487D-8ECD-2EF362CFC562Q36200403-F0B3B070-A410-4F22-A962-F53FC893F3B2Q36914407-0015B529-7B3B-4B0D-A0C6-7B45A3918A8DQ36916857-71F5E7F1-6B17-427C-BF43-5A117243141CQ36967036-9320CB72-22B6-4F5D-90E5-3B24B3A464ACQ37230970-FDCC257F-3D12-4922-BF58-9397ED8280B5Q37689592-B6A9875A-7FBC-46FD-96E8-4702E94D850EQ37689595-AB3ED4C3-3174-41CC-BF53-6F7FF4DF2E5BQ37708836-B410B1FD-2EDA-437C-BE2F-592779824EA3Q38669280-7DE1180F-41D5-4080-BCD8-0F573F79A5B8Q38733038-7DF836FE-C5BF-4117-8B16-EA78E06E8A32Q39111110-2B068471-37FE-4847-8FC7-4EB98D528C24Q39315869-DA72E7CA-DAEA-4CB6-BBD0-06BBDDBE4BD3Q39463417-345FAD0F-59EA-40FE-BA33-B659CBF7DC46Q39507845-B8D58C46-81DA-449D-938D-A97DFD53BFB5Q39527913-EA64C602-8B34-4846-A723-C7FE59922FB8Q39730112-D3DF97E4-6AD6-48CD-9D9E-F787C62A7110Q40001698-E11610CB-BA79-4738-8482-47996F706146Q41922693-F62D203B-1D68-4A05-83D6-8DD215649D2DQ42115280-C0579AF8-7050-4DEB-95AC-148FA982D7AAQ43199022-2FE4A395-16A1-45AB-BFBC-ABE0E2D2B471Q49388105-218F2DA4-6F0C-4A74-A7A7-EBC74657A90EQ54978369-FF6A41AF-6E5F-465E-9E07-56B97759D88D
P2860
Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Role of epidermal growth facto ...... itabine-mediated cytotoxicity.
@en
type
label
Role of epidermal growth facto ...... itabine-mediated cytotoxicity.
@en
prefLabel
Role of epidermal growth facto ...... itabine-mediated cytotoxicity.
@en
P2093
P2860
P356
P1433
P1476
Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity
@en
P2093
A M Chinnaiyan
S A Tomlins
T S Lawrence
P2860
P2888
P304
P356
10.1038/SJ.ONC.1210129
P407
P577
2006-12-04T00:00:00Z
P5875
P6179
1035577810